WallStSmart

Core Scientific, Inc. Common Stock (CORZ)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Core Scientific, Inc. Common Stock generates 23% more annual revenue ($319.02M vs $258.90M). ZEPP leads profitability with a -15.5% profit margin vs -90.5%. ZEPP earns a higher WallStSmart Score of 38/100 (F).

CORZ

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -2.79

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CORZ.

ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.01

$28.81 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CORZ2 strengths · Avg: 10.0/10
EPS GrowthGrowth
61.2%10/10

Earnings expanding 61.2% YoY

Debt/EquityHealth
-0.9410/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

CORZ4 concerns · Avg: 2.3/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-16.0%2/10

Revenue declined 16.0%

Free Cash FlowQuality
$-121.74M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-2.792/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CORZ

The strongest argument for CORZ centers on EPS Growth, Debt/Equity.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : CORZ

The primary concerns for CORZ are Return on Equity, Revenue Growth, Free Cash Flow.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

CORZ profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

CORZ carries more volatility with a beta of 6.36 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

ZEPP generates stronger free cash flow (-26M), providing more financial flexibility.

Bottom Line

ZEPP scores higher overall (38/100 vs 29/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Core Scientific, Inc. Common Stock

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Core Scientific, Inc. provides blockchain and artificial intelligence (AI) infrastructure services in the United States. The company is headquartered in Austin, Texas.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?